Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has seen its drug golidocitinib go from marketing approval to first prescriptions in a record time of just two days in China. This marks a significant milestone, as golidocitinib is the first and only approved Janus kinase 1 (JAK1) selective inhibitor globally for the treatment of relapsed or refractory (r/r) peripheral T-Cell lymphoma (PTCL) patients. The indication was granted fast-track status in the U.S. in February 2022.
This swift market launch follows a similar achievement by Dizal Pharma’s epidermal growth factor receptor (EGFR) inhibitor, sunvozertinib, which set a shipment record in August 2023 by launching just four days after receiving approval.- Flcube.com
